All about 2024 Saxenda lawsuit

Latest news on 2024 Saxenda lawsuit: Saxenda (Liraglutide) is a new prescription weight loss drug for the treatment of clinical obesity. Saxenda is manufactured by Novo Nordisk. The active ingredient in Saxenda is Liraglutide. Liraglutide works by imitating the effects of glucagon-like peptide (“GLP-1”), a hormone produced in the intestines that signal to the brain when you are full. The drug essentially suppresses appetite by tricking the brain. It seems to work for some patients to combat obesity. See even more information at Saxenda lawsuit.

While previous studies found a link between diabetics who take Glucagon-like peptide-1 receptor agonists and an increased risk of gastrointestinal side effects, another study examined the risks of people taking GLP-1 agonists strictly for weight loss such as Saxenda. The study included 613 patients taking Wegovy, Ozempic and Rybelsus and 4,144 taking Saxenda and compared them to 654 patients on bupropion-naltrexone (Contrave), a popular weight loss medication that is not a GLP-1 drug. The study also found that 11 of the patients on semaglutide and 372 patients on liraglutide faced gastrointestinal problems, compared to only 22 patients on bupropion-naltrexone.

The FDA said it has received reports through its adverse events tracking system of people on the drugs experiencing stomach paralysis that sometimes has not resolved by the time it is reported. Additionally, the American Society of Anesthesiologists warned that patients should stop GLP-1 agonists a week before surgery due to the increased risk that individuals will regurgitate food during surgery, even if they have fasted as directed. If someone vomits under anesthesia it can sometimes cause food and acid in the stomach to make their way into the lungs, possibly causing pneumonia and other similar problems after an operation.

A resident of Kentucky has initiated a lawsuit against Novo Nordisk A/S and its subsidiaries, accusing the company of failing to warn about the potential risk of permanent stomach paralysis caused by its weight loss medication, Saxenda (liraglutide). The plaintiff consumed Saxenda from March 2019 to April 2021 and is now experiencing gastroparesis, which has resulted in severe consequences such as persistent vomiting and abdominal pain, requiring multiple visits to the hospital. The lawsuit alleges that since the drug’s approval by the FDA in 2014, Novo Nordisk has promoted Saxenda as a weight loss solution without adequately disclosing the potential for gastrointestinal disorders, despite clinical trials indicating such risks.

Additionally, there may be other factors at play that contribute to the development of gastroparesis in individuals who have taken Saxenda such as diabetes mellitus, Parkinson’s disease, following surgery, or with some medications. Notwithstanding, it cannot be seriously debated that there has been a steady increase in the number of individuals who took Saxenda or drugs in the same class and developed gastroparesis. Jaclyn Bjorklund had been prescribed Ozempic for the management of type 2 diabetes for more than a year before she was switched to Mounjaro. Bjorklund claims that her use of both Ozempic and Mounjaro resulted in severe gastrointestinal events, including “severe vomiting, stomach pain, gastrointestinal burning, being hospitalized for stomach issues on several occasions including visits to the emergency room, [and] teeth falling out due to excessive vomiting, requiring additional medications to alleviate her excessive vomiting and throwing up whole food hours after eating.”

Saxenda and Persistent Vomiting – Some of the most serious and debilitating side effects of Saxenda is persistent vomiting along with gastroparesis. Gastroparesis is a condition that affects the normal movement of the muscles in the stomach, causing delayed emptying of the stomach’s contents. This can lead to symptoms such as nausea, vomiting, bloating, and abdominal pain. Recent studies have suggested a potential link between the use of Saxenda and gastroparesis. A study examining the risks of people taking GLP-1 agonists for weight loss, including Saxenda, found that patients taking these medications had a 3.67 times greater risk of developing gastroparesis compared to those taking a different weight loss medication, Contrave.

Moreover, healthcare professionals have reported an increase in the number of patients presenting with severe gastrointestinal issues, such as persistent vomiting, after starting Saxenda or similar GLP-1 agonist medications. These reports have raised significant concerns about the potential for Saxenda to contribute to the development of gastroparesis and other debilitating Saxenda side effects. Intestinal blockages have been reported by certain individuals who have taken Saxenda (liraglutide). These blockages can hinder the movement of food and waste through the intestines, leading to intense discomfort, swelling, and vomiting. It appears that this one of the Saxenda side effects is more prevalent in males and in those who have been using the medication for a shorter duration. In 2017, eight cases were documented, with the majority of them requiring surgical intervention. Nevertheless, the specific process by which Saxenda induces these blockages is still not fully understood.

Saxenda has been linked to an increased risk of kidney failure, which can have severe consequences if left untreated. Additionally, individuals taking Saxenda may experience episodes of low blood sugar, which can be particularly dangerous for those with pre-existing conditions like diabetes.

If you took Saxenda and developed gallbladder disease, Saxenda stomach paralysis, or any other serious Saxenda side effects, contact Timothy L. Miles, a Sazenda lawyer in Nashville, today. ?You may be eligible for a Saxenda Lawsuit ?and possibly may be entitled to substantial compensation. Find extra information on

?Timothy L. Miles is a plaintiff’s lawyer in Nashville, Tennessee, and a nationally known top-rated class action and product liability lawyer who has been leading the fight to protect the rights of injured victims for over 20 years.

Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for injured victims, consumers, and shareholders, shaped precedent-setting decisions, and delivered real reforms. Judges and peers have repeatedly recognized Mr. Miles’ relentless advocacy for the underdog, as well as his unbendable ethical standards.